Ausgabe Sonderheft 1/2017
Lp(a) – The underestimated cardiovascular risk factor
Inhalt (11 Artikel)
Editorial Lp(a) – the underestimated cardiovascular risk factor
Klaus-Peter Mellwig
Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention?
Klaus-Peter Mellwig, Dieter Horstkotte, Frank van Buuren
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
P. Grützmacher, B. Öhm, S. Szymczak, C. Dorbath, M. Brzoska, C. Kleinert
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies
Evelyn Orsó, Gerd Schmitz
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines
Reinhard Klingel, Andreas Heibges, Cordula Fassbender
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on
V. J. J. Schettler, C. L. Neumann, C. Peter, T. Zimmermann, U. Julius, E. Roeseler, F. Heigl, P. Grützmacher, H. Blume, A. Vogt
Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis
Franz Heigl, Reinhard Hettich, Erich Mauch, Reinhard Klingel, Cordula Fassbender
Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease
Frank van Buuren, Dieter Horstkotte, Cornelius Knabbe, Dennis Hinse, Klaus Peter Mellwig